Literature DB >> 9208481

Neuropeptidergic innervation of human nasal mucosa in various pathological conditions.

S Y Fang1, C L Shen.   

Abstract

This study aims to investigate the roles of neuropeptides in the pathophysiology of human nasal diseases. By using immunohistochemistry and radioimmunoassay, we detected the presence, distribution and concentrations of the following neuropeptides in human nasal tissue: vasoactive intestinal peptides (VIP), neuropeptide Y (NPY), substance P (SP), and calcitonin gene-related peptides (CGRP). This was performed in human nasal inferior turbinate mucosa from 20 patients with allergic rhinitis, twenty-five patients with chronic hypertrophic rhinitis and 10 patients without any nasal disease conditions. The presence and distribution of NPY. CGRP and SP fibers among the three subject groups displayed no evident differences. VIP fibers were densely stained around the vessels in the allergic group. In contrast, these fibers were more prominently distributed around the submucosal glands of the chronic hypertrophic rhinitis group. The concentration of VIP and SP in human nasal inferior turbinate showed a significant increase in allergic subjects. Thus, VIP may be revelant to the hypertrophic changes of the nasal mucosa. Both SP and VIP may play significant neuroimmunological roles in the pathogenesis of allergic rhinitis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9208481

Source DB:  PubMed          Journal:  Proc Natl Sci Counc Repub China B        ISSN: 0255-6596


  3 in total

Review 1.  Taste receptors in innate immunity.

Authors:  Robert J Lee; Noam A Cohen
Journal:  Cell Mol Life Sci       Date:  2014-10-17       Impact factor: 9.261

2.  Neuropeptide immunofluorescence in human nasal mucosa: assessment of the technique for vasoactive intestinal peptide (VIP).

Authors:  Jeferson Cedaro de Mendonça; José Eduardo Lutaif Dolci
Journal:  Braz J Otorhinolaryngol       Date:  2005-08-02

Review 3.  Mechanisms of allergic rhinitis.

Authors:  J N Baraniuk
Journal:  Curr Allergy Asthma Rep       Date:  2001-05       Impact factor: 4.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.